A new medical device developed by Florida-based Hamilton Devices could be used to treat the Florida hospitalization of a man who was allegedly exposed to the Ebola virus.
The company announced Wednesday that it has signed a multiyear deal to license the technology, which uses an ultrasound to deliver tiny doses of a compound called tetracycline.
The tetracecyline is the active ingredient in a cream commonly used to mask the appearance of the Ebola symptoms.
“Tetracyclecin is an excellent maskant, which will allow patients to remain healthy while minimizing the risk of transmission to other healthcare workers,” the company said in a statement.
“It has been proven to effectively treat mild Ebola infections, including a few deaths, and is a natural and effective treatment for most patients.”
A company spokeswoman did not immediately respond to a request for comment.
Tetracecline is already being used in the treatment of severe cases of Ebola in the United States.
The FDA approved tetraclime in June, and the FDA said it has received about 2,000 reports of its use to treat patients with Ebola.
“We have been receiving reports of tetraclime’s effectiveness in the field, and we are working to develop and introduce it to other countries in the near future,” said Scott Schoenbaum, vice president for research and development for Hamilton Devices, in a news release.
The new facial tonic, which was developed in partnership with the U.S. Centers for Disease Control and Prevention, is designed to work as an external nasal spray that can be used either orally or nasally.
The FDA said in the release that it expects the device to be approved for use in hospitals within 90 days.
The device is expected to cost about $1,500, with a launch expected in the fall.